 | |
| Clinical data | |
|---|---|
| Routes of administration | Oral, Rectal |
| Legal status | |
| Legal status |
|
| Identifiers | |
| |
| CAS Number | |
| PubChemCID | |
| ChemSpider | |
| UNII | |
| CompTox Dashboard(EPA) | |
| Chemical and physical data | |
| Formula | C20H25NO |
| Molar mass | 295.426 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
Methoxphenidine (methoxydiphenidine,2-MeO-Diphenidine,MXP) is adissociative of the diarylethylamine class that has been sold online as adesigner drug.[1][2] Methoxphenidine was first reported in a 1989 patent where it was tested as a treatment for neurotoxic injury.[3] Shortly after the 2013 UK ban on arylcyclohexylamines methoxphenidine and the related compounddiphenidine became available on the gray market, where it has been encountered as a powder and in tablet form.[4] Though diphenidine possesses higher affinity for the NMDA receptor, anecdotal reports suggest methoxphenidine has greater oral potency.[1] Of the three isomericanisyl-substituents methoxphenidine has affinity for theNMDA receptor that is higher than 4-MeO-diphenidine but lower than 3-MeO-diphenidine,[3][5] astructure–activity relationship shared by thearylcyclohexylamines.[6]
Acute methoxphenidine intoxication has been reported to produce confusion, hypertension, and tachycardia that was responsive to treatment with intravenouslorazepam,[7][8] methoxphenidine has also been associated with three published fatalities[9] and one case ofimpaired driving.[10]
Psychotic episodes have also been reported, including a murder in June 2014.[11]
As of October 2015 MXP is a controlled substance in China.[12]
MXP is also banned in Sweden.[13]
In Canada, MT-45 and its analogues were made Schedule I controlled substances, which includes DPD[clarification needed] in its structural group.[14] Possession without legal authority can result in maximum seven years imprisonment. Further,Health Canada amended theFood and Drug Regulations in May, 2016 to classify explicitly DPD as a restricted drug. Only those with a law enforcement agency, person with an exemption permit or institutions with Minister's authorization may possess the drug.
In Australia, theTherapeutic Goods Administration decided to include methoxphenidine as a Prohibited substance (Schedule 9) within theStandard for the Uniform Scheduling of Medicines and Poisons alongside four other phenidine analogs on 1 October 2024.[15]
